First Phase III data for Mimetogen's dry eye compound

Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) reported top-line data from a Phase III trial of MIM-D3 for dry eye, but did not report data from a second endpoint listed for the study on clinicaltrials.gov.

The company reported the 403-patient MIM-725 trial showed that twice-daily 1% MIM-D3 significantly improved central corneal fluorescein staining vs. placebo at week 8 (p=0.0134). MIM-D3 significantly improved total corneal fluorescein staining compared to placebo (p=0.05). ...